Pfizer’s Co-Developed Sickle Cell Drug Gets Orphan Status in Europe and 2 Other Hot Stocks to Watch

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Pfizer Inc. (NYSE:PFE): Current price $28.55

GlycoMimetics has reported that the European Medicines Agency has awarded orphan drug status in the European Union for GMI-1070, which is being developed in partnership with Pfizer in Sickle Cell Disease. The drug designation for GMI-1070 (rivipansel sodium) is for the treatment of vaso-occlusive crisisin patients who are suffering from sickle cell disease. Orphan drug designation in the European Union is given to products that are created for the diagnosis, prevention, or treatment of rare diseases which are life-threatening or very serious.

pfe-20130913

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business